Nora Khaldi – A Pep in her Stride at Nuritas!
6th January 2025
Nuritas, a trailblazer in AI-powered peptide discovery, has recently successfully closed an oversubscribed $42 million Series C funding round. This funding marks a pivotal moment in Nuritas’ mission to improve the lives of billions by redefining the future of health and nutrition through groundbreaking ingredient innovation.
The round was led by M&G Investments, on behalf of its Catalyst strategy—a purpose-led initiative supporting transformative businesses addressing global social and environmental challenges.
On the news, Founder & CEO of Nuritas, Dr. Nora Khaldi posted: “We are thrilled to have M&G Investments Catalyst on board as we continue to advance our mission at Nuritas. Our Magnifier AI platform is designed to revolutionize the discovery of bioactive peptides, unlocking a world of possibilities for affordable health and nutritional benefits. This investment not only validates the hard work and dedication of our incredible team but also empowers us to scale our operations and bring our innovative solutions to a broader audience.
McWin Capital Partners, a private equity and venture capital firm focused on high-growth companies in the food ecosystem, also joined as a key investor, further solidifying Nuritas’ foundation for global expansion. Current investors Grosvenor and ECBF also participated in the round.
“McWin Capital Partners are the perfect partners to join us on this journey and help us continue to innovate and grow the business, said Dr. Khaldi recently. “Their experience working in the food sector and with companies on the cutting edge of innovation will be a huge asset to our team and to the benefit of our customer network. We look forward to the partnership.”
Revolutionizing Ingredient Innovation
Most ingredients available today fail to meet the health and wellness demands of modern consumers. This is demonstrated by the huge health crisis we are experiencing globally. Developing new health-focused ingredients is slow and a costly process taking decades and costing 10s to 100s of millions.
Rooted in years of deep science Nuritas is changing the paradigm of ingredients discovery by bringing to market previously inaccessible health promoting peptide ingredients discovered in various food plant sources.
“Our mission is to improve the lives of billions by creating ingredients that address pressing global health challenges,” said Dr. Nora Khaldi,
“Through our science-first approach, we are fundamentally shifting the paradigm of ingredient discovery, enabling our customers to deliver healthier, differentiated products that meet the needs of today’s consumers.”
A Deep Commitment to Science and Customer-Centric Solutions Driving Market Impact
With nearly a decade of groundbreaking research, the company has built the world’s largest peptide knowledge base. Its cutting-edge AI platform Magnifier™ identifies peptides 10-50 times faster than traditional methods, with an industry-leading clinical success rate of over 80%, far exceeding industry standards of low single digits. As demonstrated by the numerous impactful customer product launches with Nuritas ingredients, Nuritas’ scientifically validated ingredients empower its partners to:
•Increase market penetration and differentiation with innovative, evidence-based products.
•Truly address end-consumer needs with solutions validated through rigorous science and clinical trials.
PeptiStrong™, Nuritas’ patented flagship peptide derived from fava beans, supports muscle generation and repair, has achieved FDA-approved GRAS (Generally Recognized as Safe) status in the U.S. and is already integrated into consumer products across multiple continents. It has been validated by three human clinical trials, demonstrating benefits like improved strength, faster recovery, and sustained energy.
Additionally, Nuritas recently launched PeptiYouth™, a peptide that reduces wrinkle depth by promoting collagen production. This breakthrough ingredient, discovered after millions of years of being hidden in nature, is now featured in skin-care products in the U.S. and Asia. Nuritas plans to introduce three new clinically validated peptide ingredients in 2025, further expanding its innovative portfolio.
Strategic Partnerships and Industry Recognition
The company’s revolutionary peptides have attracted high-profile partnerships with leading global companies, including Givaudan, Nestlé, Mars, and Sumitomo Corporation. These collaborations highlight the broad applications of Nuritas’ bioactive peptides across functional foods, dietary supplements, medical foods, cosmetics, and food technology.
Scaling for Global Growth
The $42 million funding will enable Nuritas to scale its operations, expand its global customer base, and reach more consumers worldwide.
“We are thrilled to welcome M&G’s Catalyst team and McWin Capital Partners, who share our vision of making healthier ingredients accessible to billions of people globally,” added Dr. Khaldi. “This investment, alongside the addition of experienced board members, will propel our mission to new heights.”
Pictured: Dr. Nora Khaldi, Founder & CEO of Nuritas.
